Publications

  1. Kirthika P, Jawalagatti V, Li P, Xu M, Carceles-Cordon M, Ertel A, Quinn SA, Petrylak DP, Orme JJ, Dehm SM, Antonarakis ES, Heath EI, Pandey MK, Cordon-Cardo C, Huang H, Dong H, Zhu S, Domingo-Domenech J, Rodriguez-Bravo V. Off-pore Nucleoporin sPOM121 Transcriptionally Propels beta-Catenin-driven Tumor Progression and Immune Escape in Prostate Cancer. Cancer Discov. 2025 Nov 3; 15 (11):2374-2396
    View PubMed
  2. Cheville JC, Orme JJ, Gupta S, Lucien-Matteoni F, Karnes RJ, Thapa P, Khanna A, Naik S, Sharma V, Frank I, Pagliaro L, Quevedo F, Tekin B, Knudson R, Greipp P, Brandt C, Koepplin J, Costello B, Heath E, Vasmatzis G, Florio A, Boorjian SA, Shah PH. Defining NECTIN4 Amplification and Protein Expression in Urothelial Carcinoma and Histologic Subtypes. Mod Pathol. 2025 Oct 29; 100928 [Epub ahead of print]
    View PubMed
  3. Jain P, Naqvi SAA, Tripathi N, Oberoi JK, Humayun MA, Zakharia Y, Orme JJ, Kase A, Childs DS, Chen R, Riaz IB, Singh P. Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis. Clin Genitourin Cancer. 2025 Oct 13; 102453 [Epub ahead of print]
    View PubMed
  4. Muniz M, Tsai LJ, Orme JJ, Bucheit LA, Basourakos SP, Wei N, Koch RM, Scharf Z, Gupta S, Kase AM, Rodrigues Pessoa R, Riaz IB, Kwon ED, Andrews JR, Childs DS. Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA Testing. Cancers (Basel). 2025 Sep 18; 17(18).
    View PubMed
  5. Roberson DS, Sharma V, Boorjian SA, McLeay MT 2nd, Reitano G, Nguyen MV, Orme JJ, Childs DS, Pagliaro LC, Potretzke AM, Karnes RJ, Shah P, Zganjar A, Lyon T, Tyson MD, Khanna A. Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis. Eur Urol 2025 Aug; 88 (2):212-214 Epub 2025 May 26
    View PubMed
  6. Koch RM, Muniz M, Peskey CS, Jatoi A, Ruddy KJ, Orme JJ, Pagliaro LC, Quevedo F, Costello BA, Spychalla MT, Heath EI, Zakharia Y, Singh P, Sartor O, Riaz IB, Cathcart-Rake EJ, D'Andre SD, Loprinzi CL, Childs DS. Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase Inhibitors. J Pain Symptom Manage. 2025 Aug; 70 (2):182-188 Epub 2025 May 03
    View PubMed
  7. Muniz M, Sartor O, Orme JJ, Koch RM, Scharf Z, Heath EI, Zarka JG, Kase AM, Riaz IB, Andrews JR, Thorpe MP, Tuba Kendi A, Bilgin GB, Johnson GB, Kwon ED, Childs DS. Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2025 Aug; 8(4):1087-1093. Epub 2025 Aug 05.
    View PubMed
  8. Belge Bilgin G, Bilgin C, Burkett BJ, Thorpe MP, Packard AT, Fidanli F, Childs DS, Muniz M, Orme JJ, Quevedo JF, Kizilbash SH, Kwon ED, Johnson GB, Johnson DR, Sartor O, Kendi AT. [177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases. Eur J Nucl Med Mol Imaging. 2025 Jul 21. [Epub ahead of print]
    View PubMed
  9. Muniz M, Childs DS, Andrews J, Mahmoud AM, Park S, Sartor O, Kase AM, Riaz IB, Stish BJ, Chaudhuri AA, Chauhan PS, Phillips R, Lucien F, Orme JJ. Deferral of systemic therapy in patients with oligorecurrent prostate cancer treated with metastasis-directed radiotherapy. Ann Transl Med. 2025 Jun 27; 13 (3):29 Epub 2025 June 24
    View PubMed
  10. Lee MS, Moschini M, Britton CJ, Longoni M, Tarrell RF, Martin AJ, Traughber BJ, Stish BJ, Orme JJ, Shah PH, Frank I, Jeffrey Karnes R, Boorjian SA, Sharma V. Development and external validation of a local pelvic recurrence risk score after radical cystectomy: identifying the ideal candidate for adjuvant radiation clinical trials. Urology. 2025 Jun 15 Epub 2025 June 15
    View PubMed
  11. Naqvi SAA, Riaz IB, Bibi A, Khan MA, Imran M, Khakwani KZR, Raina A, Anjum MU, Cobran EK, Warner JL, Hussain SA, Singh P, Childs DS, Baca SC, Orme JJ, Mateo J, Agarwal N, Gillessen S, Murad MH, Sartor O, Bryce AH. Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysis. Eur Urol. 2025 Jun; 87 (6):626-640 Epub 2025 Jan 23
    View PubMed
  12. Orme JJ, Antonarakis ES, Dehm SM. CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer. Nat Cancer. 2025 May; 6 (5):740-742
    View PubMed
  13. Belge Bilgin G, Lucien-Matteoni F, Chaudhuri AA, Orme JJ, Childs DS, Muniz M, Li GG, Chauhan PS, Lee S, Gupta S, Thorpe MP, Johnson DR, Johnson GB, Kendi AT, Sartor O. Current and future directions in theranostics for neuroendocrine prostate cancer. Cancer Treat Rev. 2025 May; 136:102941. Epub 2025 Apr 09.
    View PubMed
  14. Smith KER, Ayers-Ringler JR, Orme JJ, Lucien F, Kim Y, Winters JL, Mansfield AS. Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin. Sci Rep. 2025 Apr 16; 15 (1):13174
    View PubMed
  15. Andrews JR, Kim Y, Horjeti E, Arafa A, Gunn H, De Bruycker A, Phillips R, Song D, Childs DS, Sartor OA, Orme JJ, Chaudhuri AA, Tran P, Kiess A, Sutera P, Mercier C, Ost P, Park SS, Lucien F. PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts. Clin Cancer Res. 2025 Mar 17; 31 (6):1142-1149
    View PubMed
  16. Orme JJ, Zhang H, Lingamaneni P, Kim Y, Lavoie R, Dorr M, Dizona P, Hirdler J, Bering EA, Gicobi JK, Hsu M, Dale H, Childs DS, Kottschade LA, McWilliams RR, Block MS, Mansfield AS, Markovic SN, Olivier K, Owen D, Lester S, Ma D, Dronca RS, Dong H, Lucien F, Packard AT, Winters JL, Park SS. Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial. Nat Commun. 2025 Mar 13; 16 (1):2507
    View PubMed
  17. Hwang J, Likasitwatanakul P, Deshmukh SK, Wu S, Kwon JJ, Toye E, Moline D, Evans MG, Elliott A, Passow R, Luo C, John E, Gandhi N, McKay RR, Heath EI, Nabhan C, Reizine N, Orme JJ, Domingo Domenech JM, Sartor O, Baca SC, Dehm SM, Antonarakis ES. Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes. Clin Cancer Res. 2025 Mar 3; 31 (5):936-948
    View PubMed
  18. Mosalem O, Tan W, Bryce AH, Dronca RS, Childs DS, Pagliaro LC, Orme JJ, Kase AM. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis. Prostate Cancer Prostatic Dis. 2025 Mar; 28 (1):138-144 Epub 2024 Feb 10
    View PubMed
  19. Chauhan PS, Alahi I, Sinha S, Ledet EM, Mueller R, Linford J, Shiang AL, Webster J, Greiner L, Yang B, Ni G, Dang HX, Saha D, Babbra RK, Feng W, Harris PK, Qaium F, Duose DY, Alexander SE, Sherry AD, Jaeger EB, Miller PJ, Caputo SA, Orme JJ, Lucien F, Park SS, Tang C, Pachynski RK, Sartor O, Maher CA, Chaudhuri AA. Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer. Clin Cancer Res. 2025 Jan 6; 31 (1):151-163
    View PubMed
  20. Muniz M, Sartor O, Orme JJ, Koch RM, Rosenow HR, Mahmoud AM, Andrews JR, Kase AM, Riaz IB, Belge Bilgin G, Thorpe MP, Kendi AT, Johnson GB, Ravi P, Kwon ED, Childs DS. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617. J Nucl Med. 2024 Dec 03; 65(12):1932-1938.
    View PubMed
  21. Belge Bilgin G, Burkett BJ, Bilgin C, Orme JJ, Childs DS, Rincon MM, Abdelrazek AS, Johnson DR, Johnson GB, Kwon ED, Sartor O, Kendi AT. Neurologic Symptoms After 177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. J Nucl Med. 2024 Sep 03; 65(9):1402-1408.
    View PubMed
  22. Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer. Eur Urol Oncol. 2024 Aug; 7 (4):877-887 Epub 2023 Dec 09
    View PubMed
  23. Ahmed ME, Mahmoud AM, Reitano G, Zeina W, Lehner K, Day CA, Riaz I, Childs DS, Orme JJ, Tuba Kendi A, Johnson GB, Jeffrey Karnes R, Kwon ED, Andrews JR. Survival Patterns Based on First-site-specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same? Eur Urol Open Sci. 2024 Aug; 66:38-45 Epub 2024 June 26
    View PubMed
  24. Syc-Mazurek SB, Zhao-Fleming H, Guo Y, Tisavipat N, Chen JJ, Zekeridou A, Kournoutas I, Orme JJ, Block MS, Lucchinetti CF, Mustafa R, Flanagan EP. MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use. Neurol Neuroimmunol Neuroinflamm. 2024 Jul; 11 (4):e200249 Epub 2024 May 02
    View PubMed
  25. Kase AM, Gleba J, Miller JL, Miller E, Petit J, Barrett MT, Zhou Y, Parent EE, Cai H, Knight JA, Orme J, Reynolds J, Durham WF, Metz TM, Meurice N, Edenfield B, Alasonyalilar Demirer A, Bilgili A, Hickman PG, Pawlush ML, Marlow L, Wickland DP, Tan W, Copland JA 3rd. Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2024 Jun 04; 23(6):823-835.
    View PubMed
  26. Carceles-Cordon M, Orme JJ, Domingo-Domenech J, Rodriguez-Bravo V. The yin and yang of chromosomal instability in prostate cancer. Nat Rev Urol. 2024 Jun; 21 (6):357-372 Epub 2024 Feb 02
    View PubMed
  27. Muniz M, Loprinzi CL, Orme JJ, Koch RM, Mahmoud AM, Kase AM, Riaz IB, Andrews JR, Thorpe MP, Johnson GB, Kendi AT, Kwon ED, Nauseef JT, Morgans AK, Sartor O, Childs DS. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. Cancer Treat Rev. 2024 Jun; 127:102748 Epub 2024 Apr 30
    View PubMed
  28. Miller CD, Lozada JR, Zorko NA, Elliott A, Makovec A, Radovich M, Heath EI, Agarwal N, Mckay RR, Garje R, Bastos BR, Hoon DSB, Orme JJ, Sartor O, VanderWalde A, Nabhan C, Sledge G, Shenderov E, Dehm SM, Lou E, Miller JS, Hwang JH, Antonarakis ES. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies. Cancer Res Commun. 2024 May 30; 4 (5):1369-1379
    View PubMed
  29. Mahmoud AM, Moustafa A, Day C, Ahmed ME, Zeina W, Marzouk UM, Basourakos S, Haloi R, Mahon M, Muniz M, Childs DS, Orme JJ, Riaz IB, Kendi AT, Stish BJ, Davis BJ, Kwon ED, Andrews JR. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies. Cancers (Basel). 2024 May 30; 16 (11)
    View PubMed
  30. Mahmoud AM, Orme JJ, Childs DS, Ahmed ME, Rajkumar A, Kwon ED, Andrews JR. Prostate Cancer and Malignant Ascites: The Mayo Clinic Experience With a Rare and Aggressive Disease Progression. Clin Genitourin Cancer. 2024 Apr; 22 (2):291-294 Epub 2023 Nov 23
    View PubMed
  31. Muniz M, Childs DS, Orme JJ, Johnson GB, Sartor O. Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation Therapy. Clin Nucl Med. 2024 Apr 1; 49 (4):e164-e165 Epub 2024 Feb 06
    View PubMed
  32. Mahmoud AM, Ahmed ME, Kendi AT, Thorpe M, Johnson GB, Riaz IB, Orme JJ, Kwon ED, Andrews JR, Childs DS. Low PSA radiographic disease progression on C11-choline PET. BJUI Compass. 2024 Mar; 5 (2):319-324 Epub 2023 Oct 25
    View PubMed
  33. Mahmoud AM, Childs DS, Ahmed ME, Tuba Kendi A, Johnson GB, Orme JJ, Stish BJ, Phillips RM, Park SS, Davis BJ, Andrews JR, Kwon ED. Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis. Prostate. 2024 Feb; 84 (3):237-244 Epub 2023 Oct 29
    View PubMed
  34. Belge Bilgin G, Bilgin C, Burkett BJ, Orme JJ, Childs DS, Thorpe MP, Halfdanarson TR, Johnson GB, Kendi AT, Sartor O. Theranostics and artificial intelligence: new frontiers in personalized medicine. Theranostics. 2024; 14(6):2367-2378. Epub 2024 Mar 25.
    View PubMed
  35. Belge Bilgin G, Bilgin C, Childs DS, Orme JJ, Burkett BJ, Packard AT, Johnson DR, Thorpe MP, Riaz IB, Halfdanarson TR, Johnson GB, Sartor O, Kendi AT. Performance of ChatGPT-4 and Bard chatbots in responding to common patient questions on prostate cancer 177Lu-PSMA-617 therapy. Front Oncol. 2024; 14:1386718. Epub 2024 Jul 12.
    View PubMed
  36. Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer. Clin Lung Cancer. 2023 Dec; 24 (8):689-695.e1 Epub 2023 Sept 17
    View PubMed
  37. Gicobi JK, Mao Z, DeFranco G, Hirdler JB, Li Y, Vianzon VV, Dellacecca ER, Hsu MA, Barham W, Yan Y, Mansfield AS, Lin Y, Wu X, Hitosugi T, Owen D, Grams MP, Orme JJ, Lucien F, Zeng H, Park SS, Dong H. Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8(+) T cells via ME1 up-regulation. Sci Adv. 2023 Nov 17; 9 (46):eadi2414 Epub 2023 Nov 15
    View PubMed
  38. Kochan DC, Novotny PJ, Cathcart-Rake EJ, Orme JJ, Tevaarwerk AJ, Ruddy KJ, Childs DS. An evaluation of the effect of lithium on taxane-induced neuropathy. Support Care Cancer. 2023 Apr 25; 31(5):299.
    View PubMed
  39. Mahmoud AM, Nabavizadeh R, Rodrigues Pessoa R, Garg I, Orme J, Costello BA, Cheville J, Lucien F. Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities. Oncologist. 2023 Apr 6; 28 (4):297-308
    View PubMed
  40. Huang Z, Li X, Tang B, Li H, Zhang J, Sun R, Ma J, Pan Y, Yan B, Zhou Y, Ding D, Yan Y, Jimenez R, Orme JJ, Jin X, Yang J, Huang H, Jia Z. SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors. Cancer Res. 2023 Mar 15; 83(6):875-889.
    View PubMed
  41. Orme JJ, Mer G, Huang H. Hidden tricks in MATH: Hypermorphic mutations in SPOP tumor suppressor explained by cryo-EM. Mol Cell 2023 Mar 2; 83 (5):655-656
    View PubMed
  42. Gottlich HC, Nabavizadeh R, Dumbrava M, Rodrigues Pessoa R, Mahmoud AM, Garg I, Orme J, Costello BA, Cheville J, Lucien F. Emerging antibody-drug conjugate therapies and targets for metastatic renal cell carcinoma. Kidney Cancer. 2023; 7 (1):161-72
  43. Childs DS, Helfinstine DA Jr, Sangaralingham L, Orme JJ, O'Sullivan CC, Loprinzi CL, Ruddy KJ. Slow Uptake of an Effective Therapy: Patterns of Olanzapine Prescribing for Those Receiving Highly Emetogenic Chemotherapy. JCO Oncol Pract. 2022 Dec; 18(12):e1953-e1960. Epub 2022 Oct 31.
    View PubMed
  44. Lucien F, Kim Y, Qian J, Orme JJ, Zhang H, Arafa A, Abraha F, Thapa I, Tryggestad EJ, Harmsen WS, Kosti J, Ali H, Lowe VJ, Johnson GB, Kwon ED, Dong H, Park SS. Tumor-Derived Extracellular Vesicles Predict Clinical Outcomes in Oligometastatic Prostate Cancer and Suppress Antitumor Immunity. Int J Radiat Oncol Biol Phys. 2022 Nov 15; 114 (4):725-737 Epub 2022 June 04
    View PubMed
  45. Chinniah S, Stish B, Costello BA, Pagliaro L, Childs D, Quevedo F, Lucien F, Bryce A, Park SS, Orme JJ. Radiation Therapy in Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2022 Nov 15; 114 (4):684-692 Epub 2022 July 22
    View PubMed
  46. Desai AP, Scheckel CJ, Soderberg LC, Jensen CJ, Orme JJ, Tella SH, Kommalapati A, Pritchett JC, Khera N, Mahipal A, Go RS, Mayo Clinic Hematology and ONcology Outcomes Research (HONOR) Group. Economic Cost and Sustainability of Oral Therapies in Precision Oncology. JCO Oncol Pract. 2022 Aug; 18 (8):e1247-e1254 Epub 2022 May 26
    View PubMed
  47. Mahmoud AM, Frank I, Orme JJ, Lavoie RR, Thapa P, Costello BA, Cheville JC, Gupta S, Dong H, Lucien F. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer. BMC Urol. 2022 Jun 24; 22 (1):90 Epub 2022 June 24
    View PubMed
  48. Davidson TM, Foster N, Lucien F, Markovic S, Dong H, Winters JL, Park SS, Orme JJ. Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy. BMJ Open. 2022 May 12; 12 (5):e050112
    View PubMed
  49. Lindner AK, Furlan T, Orme JJ, Tulchiner G, Staudacher N, D'Andrea D, Culig Z, Pichler R. HUS1 as a Potential Therapeutic Target in Urothelial Cancer. J Clin Med. 2022 Apr 15; 11 (8)
    View PubMed
  50. Orme JJ, Pagliaro LC, Quevedo JF, Park SS, Costello BA. Rational Second-Generation Antiandrogen Use in Prostate Cancer. Oncologist. 2022 Mar 4; 27 (2):110-124
    View PubMed
  51. Desai A, Scheckel C, Jensen CJ, Orme J, Williams C, Shah N, Leventakos K, Adjei AA. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020. JAMA Netw Open. 2022 Jan 4; 5 (1):e2144923 Epub 2022 Jan 04
    View PubMed
  52. Chinniah S, Stish B, Costello BA, Pagliaro L, Childs D, Quevedo F, Lucien F, Bryce A, Park SS, Orme JJ. Radiation therapy in oligometastatic prostate cancer. International Journal of Radiation Oncology, Biology, Physics. 2022; 114 (4):684-92
  53. Zhang H, Orme JJ, Abraha F, Stish BJ, Lowe VJ, Lucien F, Tryggestad EJ, Bold MS, Pagliaro LC, Choo CR, Brinkmann DH, Iott MJ, Davis BJ, Quevedo JF, Harmsen WS, Costello BA, Johnson GB, Nathan MA, Olivier KR, Pisansky TM, Kwon ED, Dong H, Park SS. Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in (11)C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021 Dec 1; 27 (23):6376-6383 Epub 2021 Sept 30
    View PubMed
  54. Wee CE, Costello BA, Orme JJ, Quevedo JF, Pagliaro LC. Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience. Prostate. 2021 Sep; 81 (13):938-943 Epub 2021 July 12
    View PubMed
  55. Tulchiner G, Brunner A, Schmidinger M, Staudacher N, Orme JJ, Thurnher M, Horninger W, Culig Z, Pichler R. CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma. BJU Int. 2021 Jul; 128 (1):29-32 Epub 2021 Feb 07
    View PubMed
  56. Shi L, Yan Y, He Y, Yan B, Pan Y, Orme JJ, Zhang J, Xu W, Pang J, Huang H. Mutated SPOP E3 Ligase Promotes 17betaHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression. Cancer Res. 2021 Jul 1; 81 (13):3593-3606 Epub 2021 Mar 24
    View PubMed
  57. He Y, Wei T, Ye Z, Orme JJ, Lin D, Sheng H, Fazli L, Jeffrey Karnes R, Jimenez R, Wang L, Wang L, Gleave ME, Wang Y, Shi L, Huang H. A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. Nat Commun. 2021 Mar 9; 12 (1):1521 Epub 2021 Mar 09
    View PubMed
  58. Du Y, Xie C, Ravikumar S, Orme J, Li L, Zhou XJ, Mohan C. Heightened Crescentic Glomerulonephritis in Immune Challenged 129sv Mice Is TGF-beta/Smad3 Dependent. Int J Mol Sci. 2021 Feb 19; 22 (4)
    View PubMed
  59. Wu D, Yan Y, Wei T, Ye Z, Xiao Y, Pan Y, Orme JJ, Wang D, Wang L, Ren S, Huang H. An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors. Cell Rep. 2021 Feb 16; 34 (7):108744
    View PubMed
  60. Pichler R, Lindner AK, Schafer G, Tulchiner G, Staudacher N, Mayr M, Comperat E, Orme JJ, Schachtner G, Thurnher M. Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study. J Clin Med. 2021 Feb 14; 10 (4)
    View PubMed
  61. Orme JJ, Huang H. Microenvironment-Mediated Resistance to Anti-Androgen Therapy. Cancer Cell 2020 Aug 10; 38 (2):155-157
    View PubMed
  62. Orme JJ, Enninga EAL, Lucien-Matteoni F, Dale H, Burgstaler E, Harrington SM, Ball MK, Mansfield AS, Park SS, Block MS, Markovic SN, Yan Y, Dong H, Dronca RS, Winters JL. Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. J Immunother Cancer. 2020 Aug; 8 (2)
    View PubMed
  63. Orme JJ, Jazieh KA, Xie T, Harrington S, Liu X, Ball M, Madden B, Charlesworth MC, Azam TU, Lucien F, Wootla B, Li Y, Villasboas JC, Mansfield AS, Dronca RS, Dong H. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology. 2020; 9 (1):1744980 Epub 2020 Apr 14
    View PubMed
  64. Orme JJ, Sidana S, Gonsalves WI. 59-Year-Old Man With Fatigue, Weight Loss, and Hepatomegaly. Mayo Clin Proc. 2018 Oct; 93 (10):1525-1529 Epub 2018 Aug 10
    View PubMed
  65. Orme J, Purushotham D. Axillary Mass and Hypercalcemia: The Value of a Physical Examination. Am J Med. 2017 Dec; 130 (12):e541-e542 Epub 2017 July 17
    View PubMed
  66. Orme JJ, Du Y, Vanarsa K, Mayeux J, Li L, Mutwally A, Arriens C, Min S, Hutcheson J, Davis LS, Chong BF, Satterthwaite AB, Wu T, Mohan C. Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE. Clin Immunol. 2016 Aug; 169:58-68 Epub 2016 May 27
    View PubMed
  67. Orme JJ, Du Y, Vanarsa K, Wu T, Satterthwaite AB, Mohan C. Leukocyte Beta-Catenin Expression Is Disturbed in Systemic Lupus Erythematosus. PLoS One. 2016; 11 (8):e0161682 Epub 2016 Aug 22
    View PubMed
  68. Orme J, Du Y, Vanarsa K, Mayeux J, Li L, Mutwally A, Arriens C, Min S, Davis LS, Chong BF. Axl Is Altered in SLE Clinical Immunology Data in Brief. 2016.
  69. Min SY, Yan M, Du Y, Wu T, Khobahy E, Kwon SR, Taneja V, Bashmakov A, Nukala S, Ye Y, Orme J, Sajitharan D, Kim HY, Mohan C. Intra-articular nuclear factor-kappaB blockade ameliorates collagen-induced arthritis in mice by eliciting regulatory T cells and macrophages. Clin Exp Immunol. 2013 May; 172(2):217-27.
    View PubMed
  70. Guo Y, Orme J, Mohan C. A genopedia of lupus genes - lessons from gene knockouts. Curr Rheumatol Rev. 2013; 9 (2):90-9
    View PubMed
  71. Orme J, Mohan C. Macrophages and neutrophils in SLE-An online molecular catalog. Autoimmun Rev. 2012 Mar; 11 (5):365-72 Epub 2011 Oct 19
    View PubMed
  72. Orme J, Mohan C. Macrophage subpopulations in systemic lupus erythematosus. Discov Med. 2012 Feb; 13 (69):151-8
    View PubMed
  73. Gussew A, Orme J, Rzanny R, Reichenbach JR. Weighted Combination of Multichannel 1H MRS Data: Comparison of SNR and SVD Based Methods Proceedings of the German Chapter of the International Society for Magnetic Resonance in Medicine. 2008; 11.